‘Legal and regulatory issues need to be worked out’: US on

Washington, U.S. Aug. 7 (ANI): However, the Biden administration stressed that the U.S. is committed to continuing to provide assistance to India related to COVID-19, but said there are legal and regulatory issues that exist for the provision of COVID. 19 vaccines have to be developed in different countries.

To the ANI question about the delay in vaccine approval to India, White House spokeswoman Jen Psaki replied, “There are legal / regulatory issues that need to be worked out from country to country while we are delivering vaccines eager to get the vaccine and continue helping India “.

The US announced in June that it would buy a groundbreaking 500 million doses of Pfizer and donate it to nearly a hundred low and middle income countries that do not have a vaccine.

The United States has donated millions of doses of vaccine to countries like Bangladesh, Bhutan and South Korea in the past few weeks.

However, India has yet to get vaccines from the US.

During the joint media address by US Secretary of State Antony Blinken and Secretary of State S. Jaishankar last week in New Delhi, Jaishankar said that both sides stressed that they are now focusing on expanding vaccine production under the Quad “to serve them globally affordable and accessible ”. .

“We were very grateful for the support that – I would really say, the openness with which the Biden government has kept these supply chains open that has enabled us today to really increase vaccine numbers,” said Jaishankar.

When asked if a schedule to delay vaccine approval emerged in talks with the U.S. Secy of State Blinken during his visit to India, Psaki did not provide details, but said the U.S. is eager to continue to partner in order to continue Help in the form of vaccines.

“I would like to draw your attention to GoI (Government of India), but we aim to continue to be partners in order to continue to provide help in the form of vaccines,” said the White House spokesman. (ANI)